Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts. Founded in 2014, Compass focuses on developing proprietary antibody-based therapeutics to treat a variety of human diseases, with a strong emphasis on oncology.
The company’s core mission is to thoroughly address the tumor-immune synapse by utilizing combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass industrializes antibody discovery and decentralizes biologic validation through a partnership-first mentality, leveraging best-in-class technologies and top-tier academic laboratories globally. All novel scientific insights are validated extensively within Compass's own labs before proceeding to proprietary combination therapeutics aimed at human clinical trials.
In 2015, Compass secured a $120 million Series A financing to support its ambitious plans to build a fully-integrated biopharmaceutical company. The company’s robust pipeline includes three primary product candidates—CTX-009, CTX-471, and CTX-8371. CTX-009 is a bispecific antibody combining DLL4 and VEGF-A inhibitors, CTX-471 is a CD137 agonist, and CTX-8371 is a PD-1 x PD-L1 bispecific antibody. These candidates are in various stages of clinical development, targeting key pathways in angiogenesis, immune response activation, and immunosuppressive mechanisms within the tumor microenvironment.
Recently, Compass has achieved significant milestones. The company reported top-line data showing promising results in its Phase 2 COMPANION-003 trial and Phase 2/3 COMPANION-002 trial. Additionally, the FDA granted Fast Track Designation to CTX-009 in combination with paclitaxel for metastatic or locally advanced biliary tract cancer. Compass continues to make strides in advancing its product candidates through both standalone therapies and combinations with its proprietary pipeline antibodies.
Financially, Compass maintains a strong position, with a year-end 2023 cash balance of $152 million, extending its cash runway into mid-2026. The company’s net loss for 2023 was $42.5 million, showing a slight increase from the previous year, reflecting its intensified clinical and manufacturing activities.
Looking forward, Compass plans to continue its clinical trials and explore additional therapeutic areas. Key leadership changes and additions, such as the appointment of Vered Bisker-Leib, PhD, as CEO, reflect the company’s commitment to steering towards innovation and growth.
For more detailed and updated information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Compass Therapeutics (Nasdaq: CMPX) has announced two significant developments in its biliary tract cancer (BTC) program:
1. Completed enrollment of 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel alone in previously treated, unresectable advanced metastatic or recurrent BTC.
2. Approved an Investigator Sponsored Trial (IST) to study CTX-009 in the first-line setting for BTC patients at The University of Texas MD Anderson Cancer Center. This trial will add CTX-009 to the standard first-line regimen of gemcitabine, cisplatin, and durvalumab.
These developments mark significant progress in Compass Therapeutics' oncology-focused antibody-based therapeutics program, potentially expanding treatment options for BTC patients.
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 5-6, 2024.
The chat is scheduled for June 5 at 1:00-1:25 PM ET and will be webcast live. The presentation will be archived for 90 days on the company's events page.
Compass Therapeutics (Nasdaq: CMPX) has announced a leadership change effective May 28, 2024. Thomas Schuetz, M.D., Ph.D., has been appointed President and CEO, succeeding Vered Bisker-Leib, Ph.D., M.B.A., who stepped down but will continue as a Senior Consultant for 15 months. Dr. Schuetz, previously President of Research and Development and Vice Chair of the Board, expressed enthusiasm about his return to the CEO role and the progress of the company's clinical programs. The Board of Directors thanked Dr. Bisker-Leib for her contributions and wished her well in future endeavors.
Compass Therapeutics announced Phase 1 data for CTX-471, a novel CD137 agonist antibody, demonstrating anti-tumor activity in patients who progressed on PD-1 or PD-L1 inhibitors. The data will be presented at the ASCO Annual Meeting 2024. Five clinical responses were observed, including a complete response in a patient with small-cell lung cancer and partial responses in patients with melanoma and mesothelioma. CTX-471 was well tolerated, with the main dose-limiting toxicity being thrombocytopenia, which resolved. A low incidence of liver toxicity and mostly low-grade adverse events were reported. The study involved 19 patients in the dose escalation phase and 60 in the dose expansion phase.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place in New York City on May 20, 2024, with a fireside chat scheduled for 11:30 AM ET. A webcast of the chat will be available live and archived for 90 days on the company's events page. Compass Therapeutics specializes in developing antibody-based therapeutics aimed at treating various human diseases.
Compass Therapeutics, Inc. (Nasdaq: CMPX) reported their first quarter 2024 financial results and provided a business update. They received FDA Fast Track Designation for CTX-009 for the treatment of biliary tract tumors. Enrollment is progressing well in their clinical trials. They ended the quarter with $156 million in cash and marketable securities, extending their cash runway into late 2026.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
What does Compass Therapeutics, Inc. specialize in?
What are the main product candidates of Compass Therapeutics?
What recent milestones has Compass Therapeutics achieved?
Where is Compass Therapeutics headquartered?
How is Compass Therapeutics financed?
Who are the key executives at Compass Therapeutics?
What is the scientific focus of Compass Therapeutics?
What is the financial condition of Compass Therapeutics?
How does Compass Therapeutics innovate in antibody discovery?
What therapeutic areas is Compass Therapeutics exploring?
